BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 26851562)

  • 41. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
    Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
    Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial.
    ASPREE Investigator Group
    Contemp Clin Trials; 2013 Nov; 36(2):555-64. PubMed ID: 24113028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
    Goldstein JL; Whellan DJ; Scheiman JM; Cryer BL; Eisen GM; Lanas A; Fort JG
    Cardiovasc Ther; 2016 Apr; 34(2):59-66. PubMed ID: 26725920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?
    Laine L
    Aliment Pharmacol Ther; 2006 Sep; 24(6):897-908. PubMed ID: 16948802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. On the potential contribution of aspirin to healthy ageing programmes.
    Morgan GP
    Age Ageing; 2016 Mar; 45(2):e1-3. PubMed ID: 22101149
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events?
    Mutter J; Grandy R; Hulkower S; Stigleman S
    J Fam Pract; 2018 Apr; 67(4):247-248. PubMed ID: 29614147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aspirin for primary prevention of cardiovascular disease events.
    Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
    Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aspirin for primary prevention of cardiovascular disease in women.
    Jneid H
    Methodist Debakey Cardiovasc J; 2010 Nov-2011 Jan; 6(4):37-42. PubMed ID: 21088658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
    Leggio M; Bendini MG; Caldarone E; Lombardi M; Severi P; D'Emidio S; Stavri DC; Armeni M; Bravi V; Mazza A
    Diabetes Metab; 2018 Jun; 44(3):217-225. PubMed ID: 29257747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.
    Dehmer SP; O'Keefe LR; Evans CV; Guirguis-Blake JM; Perdue LA; Maciosek MV
    JAMA; 2022 Apr; 327(16):1598-1607. PubMed ID: 35471506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
    Hayden M; Pignone M; Phillips C; Mulrow C
    Ann Intern Med; 2002 Jan; 136(2):161-72. PubMed ID: 11790072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aspirin in the Prevention of Cardiovascular Disease and Cancer.
    Ricciotti E; FitzGerald GA
    Annu Rev Med; 2021 Jan; 72():473-495. PubMed ID: 33502899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
    Adly G; Plakogiannis R
    Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aspirin for primary prevention: USPSTF recommendations for CVD and colorectal cancer.
    Smith DK; Demetriou T; Weber C
    J Fam Pract; 2019 Apr; 68(3):146-151. PubMed ID: 31039213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
    Noubiap JJ; Nansseu JR
    Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
    Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
    Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin.
    Schnell O; Erbach M; Hummel M
    Diab Vasc Dis Res; 2012 Oct; 9(4):245-55. PubMed ID: 22508698
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.